Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00994344|
Recruitment Status : Completed
First Posted : October 14, 2009
Last Update Posted : February 13, 2014
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Darunavir/ritonavir Drug: Lopinavir/ritonavir||Phase 4|
The pillar of the current standard of care for highly active antiretroviral therapies (HAART) is the use of two nucleoside reverse transcriptase inhibitors (NRTIs).1 However, these agents can inhibit the mitochondrial DNA polymerase gamma, causing mitochondrial dysfunction, which, in turn, may cause NRTI-related adverse events such as peripheral neuropathy, pancreatitis, liver disturbances, lipid profile abnormalities or lipoatrophy.2 As a result, strategies aimed to avoid the long term exposure to NRTIs and their toxicities are desirable for the management of HIV-infected patients.
Monotherapy with protease inhibitors (PIs) as a simplification approach therapy after an induction period with conventional antiretroviral treatment, appears to be of great utility for minimizing mitochondrial toxicity because of NRTIs. This approach may also increase patient adherence, reduce costs and preserve future treatment options. However, concerns remain regarding compartmental HIV replication due to limited drug penetration into the central nervous system, risk factors associated with monotherapy failure as well as the extrapolation of results obtained in clinical trial settings to routine clinical practice, are still not well known.
In this regard, there are reports that have suggested that lopinavir/ritonavir (LPV/r) monotherapy may be an effective therapeutic option for treatment of HIV-1 infection in antiretroviral-naïve patients. 5,6 Moreover, some studies report that despite LPV/r allows CSF concentrations lower than plasma, its concentrations exceed levels that suppress wild-type HIV replication.7,8,9 However other authors have reported that LPV/r monotherapy results in suboptimal HIV suppression in the CSF compartment in approximately 10% of cases.10
Darunavir is the last PI with activity against wild-type and PI-resistant HIV. In ARTEMIS trial, DRV/r at doses of 800/100 mg once daily have demonstrated that it is non inferior and statistically superior than LPV/r and it is an effective treatment option for antiretroviral (ARV)-naïve patients. In this study, patients receiving once-daily DRV/r achieved high durable virologic response rates, which were comparable in patients with less favourable baseline characteristics or suboptimal adherence. In addition, they had a low discontinuation rate due to virologic failure or adverse events or both, did not develop protease inhibitor resistance upon failure, and had suitable drug exposure. 11,12
All these benefits, coupled with the higher genetic barrier, its favourable safety and plasmatic pharmacokinetic profile of DRV/r, suggest that DRV/r has the potential to be an excellent option for monotherapy simplification strategies.
The investigators propose a prospective and randomised clinical trial that compares the efficacy, safety and tolerability of DRV/r 900/100 mg monotherapy once daily versus LPV/r 400/100 monotherapy twice daily as simplification strategy in HIV-infected patients with stable NNRTI or PI-based antiretroviral regimen and sustained viral suppression.
Aside to the main goal of this project, the investigators are going to make use of the samples obtained from the CSF at 48 weeks of follow-up (as representative of the viruses replicating in the central nervous system) and genital tract and plasma at the different time points. The investigators will compare the sequence population of those organs from the different patients in order to state if viruses not found in plasma at one time point but found in reservoirs can be found in blood when the infection advance.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||73 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomised and Prospective Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||October 2012|
to switch from the triple therapy based regimens to Darunavir/ritonavir
Darunavir/ritonavir 800/100 mg once daily
Other Name: N/P
Active Comparator: Lopinavir/ritonavir
to switch from the triple therapy based regimens to Lopinavir/ritonavir
Lopinavir/ritonavir 400/100 mg twice daily
Other Name: N/P
- Plasmatic HIV-1 Viral load [ Time Frame: week 48 ]
- CD4 cell count [ Time Frame: baseline, weeks 12, 24, 36, 48 ]
- Changes in liver enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma GT, alkaline phosphatase) [ Time Frame: baseline, weeks 12, 24, 36, 48 ]
- Changes in total bilirubin [ Time Frame: baseline, weeks 12, 24, 36, 48 ]
- Changes in lipid parameters (total, HDL-, LDL-, cholesterol, triglycerides) [ Time Frame: baseline, weeks 12, 24, 36, 48 ]
- Administration of lipid-lowering drugs throughout the study (new administrations or the withdrawal of previous lipid-lowering drugs) [ Time Frame: baseline, weeks 4, 12, 24, 36, 48. ]
- Adverse events [ Time Frame: weeks 4, 12, 24, 36, 48. ]
- CSF and genital tract HIV-1 viral load [ Time Frame: baseline, weeks 24, 48 ]
- Plasmatic, CSF and genital tract trough-DRV and LPV concentration [ Time Frame: weeks 12, 24, 48 ]
- Resistance mutations in case of confirmed virological failure (plasmatic, CSF and genital tract) [ Time Frame: baseline, weeks 4, 12, 24, 36, 48. ]
- Neurocognitives changes [ Time Frame: baseline, week 48 ]
- Time to virological failure, defined as an increase in HIV RNA >50 copies in 2 determinations within 1 month. The first date with VL > 50 will be used to calculate time to virological failure. [ Time Frame: weeks 4, 12, 24, 36, 48. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00994344
|Germans Trias i Pujol Hospital|
|Badalona, Barcelona, Spain, 08916|
|Hospital Universitario de Canarias|
|Santa Cruz de Tenerife, Canarias, Spain, 38320|